Setipiprant

Overview

Setipiprant (ACT-129968) is an orally active and selective CRTH2 antagonist. Setipiprant interacts with hCRTH2 receptor with an IC 50 value of 6 nM. Setipiprant inhibits prostanoid receptors h DP 1 and h EP 2 with IC 50 values of 1290 and 2600 nM, respectively. Setipiprant can be used for the research of asthma and rhinitis.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > SARS-CoV-2 Infection | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Endocrinology | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Prostaglandin Receptor

Product Information

• Catalog No.: HY-16635
• CAS No.: 866460-33-5
• Molecular Formula: C24H19FN2O3
• Molecular Weight: 402.42
• Purity: 98.23%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (6.21 mM); Clear solution
• Availability: In-stock

Source

Original product source